Ultra-early rt-PA administration should improve patient outcome on mechanical thrombectomy: Post hoc analysis of SKIP
暂无分享,去创建一个
T. Ueda | T. Ota | H. Naito | Y. Nishiyama | K. Kimura | Mikito Hayakawa | Y. Matsumaru | R. Kanazawa | T. Higashida | K. Shigeta | N. Kato | Y. Iguchi | W. Tsuruta | T. Hirano | T. Takigawa | J. Aoki | S. Fujimoto | Y. Kamiya | K. Akaji | Y. Sakamoto | S. Okubo | Kentaro Suzuki | T. Kanamaru | Y. Takayama | K. Miki | T. Otsuka | Tomonari Saito | Masataka Takeuchi | M. Inoue | Takehiro Katano | A. Kutsuna | Mitsuhiro Iwasaki | M. Morimoto | Norihiro Ishii | Y. Koguchi | M. Takeuchi | Junya Aoki | Keigo Shigeta
[1] K. Toyoda,et al. Endovascular Therapy for Acute Stroke with a Large Ischemic Region. , 2022, The New England journal of medicine.
[2] J. Grotta,et al. Association of Endovascular Thrombectomy vs Medical Management With Functional and Safety Outcomes in Patients Treated Beyond 24 Hours of Last Known Well: The SELECT Late Study. , 2022, JAMA neurology.
[3] B. Baxter,et al. Trial of Endovascular Treatment of Acute Basilar-Artery Occlusion. , 2022, The New England journal of medicine.
[4] D. Liebeskind,et al. Trial of Thrombectomy 6 to 24 Hours after Stroke Due to Basilar-Artery Occlusion. , 2022, The New England journal of medicine.
[5] M. Wiesmann,et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial , 2022, The Lancet.
[6] L. Beenen,et al. A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke. , 2021, The New England journal of medicine.
[7] T. Ueda,et al. Effect of Mechanical Thrombectomy Without vs With Intravenous Thrombolysis on Functional Outcome Among Patients With Acute Ischemic Stroke: The SKIP Randomized Clinical Trial. , 2021, JAMA.
[8] R. Nogueira,et al. Effect of Endovascular Treatment Alone vs Intravenous Alteplase Plus Endovascular Treatment on Functional Independence in Patients With Acute Ischemic Stroke: The DEVT Randomized Clinical Trial. , 2021, JAMA.
[9] Y. Zhou,et al. Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke , 2020, New England Journal of Medicine.
[10] Thalia Shoshana Field,et al. Thrombus Migration and Fragmentation After Intravenous Alteplase Treatment , 2020, Stroke.
[11] T. Iwama,et al. Guidelines for Intravenous Thrombolysis (Recombinant Tissue-type Plasminogen Activator), the Third Edition, March 2019: A Guideline from the Japan Stroke Society , 2019, Neurologia medico-chirurgica.
[12] X. Ji,et al. Asymptomatic Intracerebral Hemorrhage May Worsen Clinical Outcomes in Acute Ischemic Stroke Patients Undergoing Thrombectomy. , 2019, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[13] Hester F. Lingsma,et al. Hemorrhagic transformation is associated with poor functional outcome in patients with acute ischemic stroke due to a large vessel occlusion , 2018, Journal of NeuroInterventional Surgery.
[14] Adnan H Siddiqui,et al. Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta-analysis. , 2016, JAMA.
[15] P. Sandercock,et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis , 2016, The Lancet Neurology.
[16] A. Demchuk,et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials , 2016, The Lancet.
[17] P. Sandercock,et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials , 2014, The Lancet.
[18] C. Molina,et al. Impact of Time to Treatment on Tissue-Type Plasminogen Activator–Induced Recanalization in Acute Ischemic Stroke , 2014, Stroke.
[19] R. Libman,et al. Is asymptomatic hemorrhagic transformation really innocuous? , 2012, Neurology.
[20] T. Eckle,et al. Ischemia and reperfusion—from mechanism to translation , 2011, Nature Medicine.
[21] K. Kimura,et al. Early stroke treatment with IV t-PA associated with early recanalization , 2010, Journal of the Neurological Sciences.
[22] K. Kimura,et al. Hemorrhagic transformation of ischemic brain tissue after t-PA thrombolysis as detected by MRI may be asymptomatic, but impair neurological recovery , 2008, Journal of the Neurological Sciences.
[23] D. Hermann,et al. Tissue plasminogen activator-induced reperfusion injury after stroke revisited. , 2007, Circulation.
[24] Werner Hacke,et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2007, The Lancet.
[25] A. Demchuk,et al. Asymptomatic Hemorrhage After Thrombolysis May Not Be Benign: Prognosis by Hemorrhage Type in the Canadian Alteplase for Stroke Effectiveness Study Registry , 2007, Stroke.
[26] A. Demchuk,et al. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy , 2000, The Lancet.
[27] David Lee Gordon,et al. Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.